Since the RNA-sequencing of cell lines expressing the mutant forms of B9/B9L and β-catenin did not reveal major changes, we postulate the interaction is critical for fine-tuning Wnt/β-catenin signaling during malignant breast cancer progression. Here, BCL9L is linked to breast carcinoma.